E. Manali (Athens, Greece), Z. Daniil (Larisa, Greece)
Late Breaking Abstract - Loss of PTEN induces alveolar epithelial cell senescence resulting in lung fibrosis via activated NF-?B
Y. Tian (Nanjing, China), C. Liu (Nanjing, China), H. Li (Nanjing, China), J. Dai (Nanjing, China), J. Chen (Wuxi, China), M. Zhou (Wuxi, China), H. Cai (Nanjing, China)
|    |
Late Breaking Abstract - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes
N. Mansouri (Boston, United States of America), G. Willis (Boston, United States of America), A. Fernandez-Gonzalez (Boston, United States of America), M. Reis (Boston, United States of America), S. Mitsialis (Boston, United States of America), S. Kourembanas (Boston, United States of America)
|  |
Late Breaking Abstract - A Deep Learning Algorithm for Classifying Fibrotic Lung Disease on High Resolution Computed Tomography
S. Walsh (London, United Kingdom), L. Calandriello (Rome, Italy), M. Silva (Parma, Italy), N. Sverzellati (Parma, Italy)
| |
Late Breaking Abstract - Idiopathic Pulmonary Fibrosis – a worldwide review of ‘real’ life’ practice: experience from a treatment feasibility review in 41 countries
M. Wijsenbeek (Rotterdam, Netherlands), F. Floricel (Mechelen, Belgium), J. Thonnard (Mechelen, Belgium), A. Fieuw (Mechelen, Belgium), P. Ford (Mechelen, Belgium), E. Santermans (Mechelen, Belgium), C. Vandenrijn (Mechelen, Belgium), T. Maher (London, United Kingdom)
| |
Late Breaking Abstract - Ten years experience of whole lung lavage for PAP cases in Songklanagarind hospital
A. Navasakulpong (Hatyai, Thailand), P. Kanmuang (Hatyai, Thailand)
| |
Late Breaking Abstract - Prognostic analysis of secondary pulmonary alveolar proteinosis: Inspection by one of the world’s largest data.
H. Ishii (Tokyo, Japan), R. Tazawa (Niigata, Japan), T. Saraya (Tokyo, Japan), Y. Inoue (Osaka, Japan), K. Nakata (Niigata, Japan)
| |
Late Breaking Abstract - Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients
A. Montgomery (Seattle, United States of America), K. Otto (Seattle, United States of America), J. Khoo (Melbourne, Australia), I. Glaspole (Melbourne, Australia)
| |